Oprean Cristina Marinela, Badau Larisa Maria, Han Robert-Alexandru, Hoinoiu Teodora, Dragomir Gabriel-Mugur, Grujic Daciana, Dragomir Tiberiu, Dema Alis
ANAPATMOL Research Center, 'Victor Babes' University of Medicine and Pharmacy of Timisoara, 300041 Timisoara, Romania.
Department of Oncology-ONCOHELP Hospital Timisoara, Ciprian Porumbescu Street, No. 59, 300239 Timisoara, Romania.
Diagnostics (Basel). 2021 Oct 22;11(11):1957. doi: 10.3390/diagnostics11111957.
With improved survival, more patients with prior breast cancer are at risk of having a second primary cancer diagnosed. The pattern and impact of second primary cancers following breast cancer is important for overall breast cancer therapeutic management. Our study is a first analysis of the trend of second primary tumours over time in terms of incidence, sites with significantly elevated risks and correlation with stage, molecular subtype and therapeutic strategies conducted in Eastern Europe in postmenopausal women with breast cancer.
Our study population included 28 patients with prior breast cancer (BC) and second primary tumours, which were diagnosed and treated in our Institution between 2004 and 2017. The criteria for selection were based on the completeness of the documentation of the first treatment for breast cancer, stage of disease, molecular subtype, the site of origin of the second tumours and the survival data.
An increased risk of second primary cancer was associated with the 51-60 years age group (53.6%), with the greater prevalence in patients living in urban environments (82.1%). The use of chemotherapy increased the risk of the occurrence of gynecological second malignancies (75%). Our study is a first analysis of the trend of second primary tumours over time in terms of identifying sites with significantly elevated risks and correlation with therapeutic strategies conducted in Eastern Europe in postmenopausal women with breast cancer.
Our study is a first analysis of the trend of second primary tumours over time in terms of correlation with luminal subtype and stage at diagnosis of primary cancer sites with significantly elevated risks and correlation with therapeutic strategies in postmenopausal women with breast cancer conducted in Eastern Europe. The reported time from primary to second primary malignancy onset, with a significantly higher rate for postmenopausal breast cancer patients, was less than one year (50%). With the advances and wider availability of genetic testing (e.g., gene panels), patients diagnosed with multiple primaries should be increasingly investigated for an underlying cancer predisposition. Postmenopausal women with breast cancer may benefit from increased surveillance and advice to avoid second malignancies.
随着生存率的提高，更多既往患乳腺癌的患者有被诊断出患第二种原发性癌症的风险。乳腺癌后第二种原发性癌症的模式和影响对于整体乳腺癌治疗管理很重要。我们的研究是对东欧绝经后乳腺癌女性中第二种原发性肿瘤随时间变化的趋势进行的首次分析，涉及发病率、风险显著升高的部位以及与分期、分子亚型和治疗策略的相关性。
我们的研究人群包括28例既往患乳腺癌（BC）且患有第二种原发性肿瘤的患者，这些患者于2004年至2017年在我们机构被诊断和治疗。选择标准基于乳腺癌首次治疗的记录完整性、疾病分期、分子亚型、第二种肿瘤的起源部位以及生存数据。
第二种原发性癌症风险增加与51 - 60岁年龄组相关（53.6%），城市环境中的患者患病率更高（82.1%）。化疗的使用增加了发生妇科第二种恶性肿瘤的风险（75%）。我们的研究是对东欧绝经后乳腺癌女性中第二种原发性肿瘤随时间变化的趋势进行的首次分析，涉及识别风险显著升高的部位以及与治疗策略的相关性。
我们的研究是对东欧绝经后乳腺癌女性中第二种原发性肿瘤随时间变化的趋势进行的首次分析，涉及与管腔亚型和原发性癌症部位诊断时分期的相关性、风险显著升高的部位以及与治疗策略的相关性。报告的从原发性到第二种原发性恶性肿瘤发病的时间，绝经后乳腺癌患者的发生率显著更高，不到一年（50%）。随着基因检测（如基因panel）的进展和更广泛应用，被诊断为多原发性癌症的患者应越来越多地接受潜在癌症易感性的调查。绝经后乳腺癌女性可能受益于加强监测和避免第二种恶性肿瘤的建议。
